|
CA2455987A1
|
|
Tetrahydroindolone and purine derivatives linked to arylpiperazines
|
|
WO03007963A1
|
|
Pyrimidine derivatives and their use in the treatment of neurodegenerative diseases
|
|
WO02085904A1
|
|
Snythesis and methods of use of purine analogues and derivatives
|
|
AU7321801A
|
|
Methods for stimulation of synthesis of synaptophysin in the central nervous system
|
|
AU7186701A
|
|
Methods for treatment of conditions affected by activity of multidrug transporters
|
|
AU7190801A
|
|
Methods for treatment of disease-induced peripheral neuropathy and related conditions
|
|
AU7321701A
|
|
Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
|
|
US6407237B1
|
|
Crystal forms of 9-substituted hypoxanthine derivatives
|
|
US6288069B1
|
|
Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
|
|
US6338963B1
|
|
Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
|
|
US6297226B1
|
|
Synthesis and methods of use of 9-substituted guanine derivatives
|
|
AU3785799A
|
|
Method for treating migraine in mammals
|
|
WO9957119A1
|
|
Novel dopamine-like 9-substituted hypoxanthine and methods of use
|
|
US6303617B1
|
|
Serotonin-like 9-substituted hypoxanthine and methods of use
|
